Cognition Therapeutics, Inc.

Affymax Technologies, N.v.

Rigel Pharmaceuticals, Incorporated

Propharmacon Inc.

Gary Charles Look

Gilbert M Rishton

Susan M Catalano

Dinesh Vinoobhai Patel

David A Campbell

Anna Katrin Szardenings

Rajinder Paul Singh

Sarkiz D Issakani

Usha V Ramesh

John S Ward

John Robert Schullek

Martin A Murphy

Brian Siesel

Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

Isoindoline compositions and methods for treating neurodegenerative disease

The present disclosure relates to novel compounds of Formula I wherein each of R, R, Rand Ris independently H; Ris selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF, SOCH, and morpholino, Ris selected from the group consisting of hydrogen, alkyl, phenyl, or —CH═C(CH); and Ris specific substituted cyclic amino groups. The invention also discloses pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurogenerative diseases, including Alzheimer's disease and cognitive decline.

Compositions for treating neurodegenerative diseases

The present disclosure relates to novel compounds, and pharmaceutical compositions thereof, useful for treating for treating neurodegenerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed. Representative members of these compounds include: 

This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides for pharmaceutical compositions comprising the compounds described in the invention for the treatment of conditions that require inhibition of ubiquitin ligases. Furthermore, the invention provides for methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound according to the invention.

Ubiquitin ligase inhibitors

The present invention provides compounds that are effective against inhibiting topoisomerase (i.e., topoisomerase I and/or topoisomerase II). These compounds are used for treating cell-proliferative disorders. In some instances, these compounds have anticancer activity, e.g., against multi-drug resistant cancers.

Topoisomerase inhibitors

This invention describes compounds and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating diseases caused by viruses such as poxviruses and retroviruses. The invention further provides for methods of treating smallpox, Herpes virus and HIV infection in patients using the compounds and compositions of the invention.

Rhodanine compositions for use as antiviral agents

Novel inhibitors of metalloproteases, in particular collagenase-1 and stromelysin-1, are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.

Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use

Novel inhibitors of metalloproteases are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.

Inhibitors of metalloproteases pharmaceutical compositions comprising

Novel inhibitors of metalloproteases, in particular collagenase-1 and stromelysin-1, are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis. ##STR1##

Growing community of inventors

Santa Clara, CA, United States of America

Gary Charles Look